| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Biomerica, Inc. (NASDAQ:BMRA), a global provider of advanced medical products, is proud to announce a major enhancement to its inFoods® IBS system, aimed at simplifying and transforming the patient experience.
Empowering Patients & Physicians Through Self-Collection
The inFoods® IBS diagnostic test has made a significant advancement with the introduction of a new patient self-collection system. This innovative system utilizes a simple, minimally invasive finger-stick device that enables patients to collect their own blood samples at home, bypassing the need to visit healthcare facilities. This enhancement enables the inFoods® IBS product to be marketed and provided nationally through telehealth and online medical providers, significantly expanding access to millions of IBS sufferers who may not live near a GI physician offering the product. The Company believes this could have a significant positive impact on inFoods® IBS revenues by reaching a broader patient population.
"Our goal is to deliver cost-effective, non-pharmaceutical solutions that manage IBS by pinpointing and eliminating specific dietary triggers," said Zack Irani, CEO of Biomerica. "This innovation is an important step to opening access to IBS patients and their healthcare providers."
Impact of IBS and Economic Burden
The American College of Gastroenterology reports that one in twenty Americans is affected by IBS, contributing to an annual expenditure of up to $10 billion in direct medical costs. Despite this significant impact, the complexity of the disorder has historically hindered the development of effective treatments, leaving many to struggle with inadequate relief.
Posted In: BMRA
